{
    "clinical_study": {
        "@rank": "56985", 
        "arm_group": [
            {
                "arm_group_label": "Paracetamol/ Caffeine Caplets", 
                "arm_group_type": "Experimental", 
                "description": "Two caplets of paracetamol/caffeine combination plus 2 placebo caplets to be administered"
            }, 
            {
                "arm_group_label": "Ibuprofen Caplets", 
                "arm_group_type": "Active Comparator", 
                "description": "Two ibuprofen caplets plus two placebo caplets to be administered"
            }, 
            {
                "arm_group_label": "Placebo Caplets", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Four placebo caplets to be administered"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this multi-center study is to assess the efficacy of headache relief of new\n      paracetamol/caffeine formulation compared to placebo and ibuprofen in episodic tension-type\n      headache (ETTH)."
        }, 
        "brief_title": "Clinical Study to Evaluate Efficacy of New Paracetamol Formulation Compared to Ibuprofen in Headache", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Headache, Tension-Type", 
        "condition_browse": {
            "mesh_term": [
                "Headache", 
                "Tension-Type Headache"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participants in good general health, and with diagnosis of ETTH with following\n             conditions:\n\n               1. number of days with the condition is historically greater than or equal to two\n                  per month;\n\n               2. severity of headaches is historically at least moderate;\n\n               3. duration of headaches is historically more than or equal to 4 hours, if\n                  untreated.\n\n                  Exclusion Criteria:\n\n          -  Participant with known or suspected hypersensitivity, allergy, intolerance or\n             contraindication to the use of any of the study medications\n\n          -  Participant has chronic tension type headache, psychiatric disease or a significant\n             cognitive disorder, or any chronic pain disorder.\n\n          -  Participant currently taking or has taken medications or herbal supplements within\n             the three months that are likely to interfere with the validity of subject-rated\n             assessments."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01842633", 
            "org_study_id": "RH01649"
        }, 
        "intervention": [
            {
                "arm_group_label": "Paracetamol/ Caffeine Caplets", 
                "description": "Caplets containing 500 milligrams (mg) of paracetamol and 65 mg of caffeine", 
                "intervention_name": "Paracetamol and Caffeine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Ibuprofen Caplets", 
                "description": "Caplets containing 200 mg of ibuprofen", 
                "intervention_name": "Ibuprofen", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Caplets", 
                "description": "Matching placebo caplets", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acetaminophen", 
                "Ibuprofen", 
                "Caffeine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 15, 2014", 
        "location": {
            "contact": {
                "email": "info@GSKClinicalSupportHD@gsk.com", 
                "last_name": "US GSK Clinical Trials Call Center", 
                "phone": "877-379-3718"
            }, 
            "contact_backup": {
                "email": "info@GSKClinicalSupportHD@gsk.com", 
                "last_name": "EU GSK Clinical Trials Call Center", 
                "phone": "+44 (0) 20 8990 4466"
            }, 
            "facility": {
                "address": {
                    "city": "Waltham", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02451"
                }, 
                "name": "PAREXEL International, LLC"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Study to Assess Efficacy Over Placebo and Speed of Onset of Pain Relief of New Paracetamol and Caffeine Tablets as Compared to Ibuprofen in Episodic Tension Type Headache", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Trials Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "SPID to be calculated as the sum of headache intensity differences at 4 hours post-dose. Pain intensity at each time point will be calculated as difference of pain intensity at baseline with pain intensity at a given time point.", 
            "measure": "Sum of pain intensity difference (SPID) of experimental formulation vs placebo", 
            "safety_issue": "No", 
            "time_frame": "Baseline to 4 hours post dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01842633"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Pain intensity at each time point will be calculated as difference of pain intensity at baseline with pain intensity at a given time point.", 
                "measure": "SPID of other treatments", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 1, 2, 3 and 4 hours post dose"
            }, 
            {
                "description": "This endpoint will be assessed as time when participants achieve pain relief scores (PRS) more than or equal to 1.", 
                "measure": "Time to perceptible headache relief", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 4 hours"
            }, 
            {
                "description": "This endpoint will be assessed as time when subjects reported a PRS \u2265 2.", 
                "measure": "Time to meaningful headache relief", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 4 hours"
            }, 
            {
                "description": "TOTPAR will be sum of products of PRS at each time point with time interval between any two time points being used.", 
                "measure": "Total pain relief (TOTPAR)", 
                "safety_issue": "No", 
                "time_frame": "1, 2, 3 and 4 hour post dose"
            }, 
            {
                "description": "Area under the time-response curve for change in headache intensity and headache relief.", 
                "measure": "Sum of TOTPAR and SPID (SPRID)", 
                "safety_issue": "No", 
                "time_frame": "1, 2, 3 and 4 hour post dose"
            }, 
            {
                "description": "Global evaluation of treatment response is to be measured by a score in a scale from: 0-very poor, 1-poor, 2-neutral [neither poor nor good], 3-good, or 4-very good).", 
                "measure": "Global Evaluation of Response to Treatment", 
                "safety_issue": "No", 
                "time_frame": "4 hours"
            }, 
            {
                "description": "Proportion of subjects that took rescue medication over the total number of subjects for a given treatment group.", 
                "measure": "Rate of rescue medication", 
                "safety_issue": "No", 
                "time_frame": "4 hours"
            }, 
            {
                "description": "Median time taken by participants who will opt for rescue medication to be determined.", 
                "measure": "Time to rescue medication", 
                "safety_issue": "No", 
                "time_frame": "4 hours"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}